An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Vitamin E and Selenium in Preventing Cataracts and Age-Related Macular Degeneration
Trial Status: complete
This clinical trial studies vitamin E and selenium in preventing cataracts and age-related macular degeneration. Vitamin E and selenium are antioxidants that may prevent or slow the growth of cataracts or age-related macular degeneration.
Inclusion Criteria
The potential S0000B (SEE) participant must be a SELECT participant at the time of registration to SEE; participants may be registered to SEE at any time after SELECT randomization; participants are registered only after they report an eye event of interest
The potential participant must report a diagnosis of age-related macular degeneration (AMD) at baseline (contact 010) or at follow-up, or a diagnosis of cataract or a cataract extraction at follow-up (effective November 1, 2009 accrual of new participants based solely on a diagnosis of cataract or a cataract extraction at follow-up is closed)
* The potential participant must report a diagnosis of age-related macular degeneration (AMD) at baseline (contact 010) or at follow-up, or a diagnosis of cataract or a cataract extraction at follow-up (effective November 1, 2009 accrual of new participants
based solely on a diagnosis of cataract or a cataract extraction at follow-up is closed)
* A participant who reported a previous diagnosis of cataract at baseline (contact 010), then reports a cataract event (another cataract diagnosis or a cataract extraction) at follow-up, is not eligible
* A participant who reported a previous diagnosis of cataract at baseline (contact 010), then reports a diagnosis of AMD at follow-up is eligible
Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines before SEE procedures are initiated; participants must have signed an applicable medical records release form and it must have been sent to Dr. William Christen at the SELECT Eye Endpoints (SEE) Center in Boston, MA by FAX (FAX #: 617/278-2030) immediately after registration to SEE
At the time of participant registration, the treating institution's name and identification (ID) number must be provided to the Statistical Center in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the database
Additional locations may be listed on ClinicalTrials.gov for NCT00784225.
I. To test whether 400 mg of vitamin E reduces the risk of visually-significant age-related macular degeneration (AMD).
II. To test whether 200 ug of selenium reduces the risk of visually-significant AMD.
III. To test whether 400 mg of vitamin E reduces the risk of cataract.
IV. To test whether 200 ug of selenium reduces the risk of cataract.
SECONDARY OBJECTIVES:
I. To test whether 400 mg of vitamin E reduces the risk of advanced AMD.
II. To test whether 200 ug of selenium reduces the risk of advanced AMD.
III. To test whether 400 mg of vitamin E reduces the risk of cataract surgery and subtypes.
IV. To test whether 200 ug of selenium reduces the risk of cataract surgery and subtypes.
OUTLINE:
Participant information on previous diagnoses of cataract and AMD are collected by questionnaires at baseline, 6 months, and annually. Medical records are collected and reviewed for patients with a diagnosis of AMD.